Custom proteins and antibodies for bioscience
is a contract services company that develops and produces plasmid DNA, recombinant proteins and antibodies specific to client requirements. Its Madison division is partnering with UW-Madison to improve manufacturing processes and efficiency. In 1998, John Ballantyne and Michael Chambers started Aldevron in a small lab at North Dakota State University. Aldevron initially specialized in plasmid DNA production for gene therapy and DNA vaccine research, and quickly grew into a well-known and respected service organization.
With the purchase of Genovac (Freiburg, Germany) in 2004, Aldevron gained the ability to make antibodies directly from plasmid DNA—a novel approach that often succeeds where conventional methods fail. Growth accelerated in August 2009, when Aldevron established a site in Madison, specializing in the use of recombinant DNA to develop and produce proteins with commercial or therapeutic value. To date, the Madison site has completed over 400 projects making more than 1,000 recombinant proteins for clients. Aldevron’s key clients are mostly top 20 pharma and biotech companies.
Drawing on UW-Madison's expertise
Dr. Ananth Krishnamurthy met with Aldevron in December of 2012 to discuss the application of Quick Response Manufacturing (QRM) to the commercial production of biological materials – an operation that involves variable and at times unpredictable processes. Since the first meeting, Aldevron has worked with Dr. Krishnamurthy and his doctoral student Tugce Martagan, to study the application and benefit of QRM in a production operation. “Aldevron places high priority on client satisfaction and, therefore, is always looking for ways to ensure outcomes that are both satisfying to the client and profitable to the company,” says Aldevron Vice President and General Manager Tom Foti. “As we learn more about the application and benefits of QRM in the production of biological materials (Bio-QRM), we will apply the method to better deal with uneven resource demands and unpredictable production processes that put at risk our ability to deliver satisfying and profitable results.”